Compare Stocks → Forget Bitcoin: This $8 Stock Is the Next Big Thing (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNTXNASDAQ:LVTXNASDAQ:MYNZNASDAQ:VSAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.00+11.1%$1.42$0.53▼$2.10$150M2.141.57 million shs617,683 shsLVTXLAVA Therapeutics$2.64-4.3%$3.02$1.13▼$6.47N/A0.6991,129 shs47,187 shsMYNZMainz Biomed$0.68+6.3%$0.92$0.60▼$6.00N/A0.28205,365 shs83,670 shsVSARVersartis$1.19$1.19$1.14▼$2.76N/AN/A479,436 shs349,963 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics0.00%+6.95%+45.99%+92.33%+266.17%LVTXLAVA Therapeutics0.00%-14.56%-6.71%+22.22%+40.43%MYNZMainz Biomed0.00%+3.02%-24.79%-32.68%-87.24%VSARVersartis0.00%0.00%0.00%0.00%0.00%[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTXContext Therapeutics2.5363 of 5 stars3.55.00.00.02.40.00.6LVTXLAVA Therapeutics1.8522 of 5 stars3.55.00.00.00.60.00.6MYNZMainz Biomed0.9057 of 5 stars3.33.00.00.00.60.80.0VSARVersartisN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics3.00Buy$6.00200.00% UpsideLVTXLAVA Therapeutics3.00Buy$6.00127.27% UpsideMYNZMainz Biomed2.50Moderate Buy$6.00782.48% UpsideVSARVersartisN/AN/AN/AN/ACurrent Analyst RatingsLatest VSAR, CNTX, LVTX, and MYNZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2024CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$4.505/16/2024CNTXContext TherapeuticsPiper Sandler CompaniesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$4.505/9/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.005/9/2024CNTXContext TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $10.004/12/2024MYNZMainz BiomedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/21/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/21/2024LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024MYNZMainz BiomedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ALVTXLAVA Therapeutics$6.77MN/AN/AN/A$3.39 per shareN/AMYNZMainz Biomed$900KN/AN/AN/A$0.27 per shareN/AVSARVersartisN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$23.96M-$1.33N/AN/AN/AN/A-136.03%-109.54%8/14/2024 (Estimated)LVTXLAVA Therapeutics-$41.97M-$1.59N/AN/AN/A-620.09%-68.54%-35.68%6/13/2024 (Estimated)MYNZMainz Biomed-$26.30M-$1.64N/A∞N/A-2,934.82%-488.05%-145.77%5/21/2024 (Estimated)VSARVersartisN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VSAR, CNTX, LVTX, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/9/2024Q4 2023MYNZMainz BiomedN/A-$0.24-$0.24-$0.24N/A$0.22 million3/21/2024Q4 2023CNTXContext Therapeutics-$0.35-$0.42-$0.07-$0.42N/AN/A3/20/2024Q4 2023LVTXLAVA Therapeutics$0.16-$0.24-$0.40-$0.24$25.00 million$0.35 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A4.234.23LVTXLAVA Therapeutics0.016.626.62MYNZMainz Biomed0.360.970.91VSARVersartisN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%LVTXLAVA TherapeuticsN/AMYNZMainz BiomedN/AVSARVersartis38.52%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics6.66%LVTXLAVA Therapeutics0.79%MYNZMainz Biomed18.20%VSARVersartis10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics575.00 million70.00 millionNot OptionableLVTXLAVA Therapeutics37N/AN/AOptionableMYNZMainz Biomed65N/AN/ANot OptionableVSARVersartisN/AN/AN/AOptionableVSAR, CNTX, LVTX, and MYNZ HeadlinesRecent News About These CompaniesJuly 21, 2023 | thestreet.com16 Biopharma Companies Besides Medivation That Are Attractive TargetsMay 11, 2023 | news.google.comJohn Newman's Stock Ratings - BenzingaMay 11, 2023 | news.google.comGlobal Human Growth Hormone Market Assessment 2023-2030 ... - Cottonwood Holladay JournalApril 11, 2023 | news.google.comHDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS ... - InvestorsObserverMarch 28, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market 2023 with Growth Overview, Developments in Manufacturing Te - openPRFebruary 15, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market is booming ... - Trending in PakistanJanuary 24, 2023 | globalnews.caInjured snowmobiler rescued from Enderby backcountryJanuary 12, 2023 | news.google.comSecret CSO: Todd Dekkinga, Zluri - IDG ConnectDecember 28, 2022 | thestreet.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyDecember 21, 2022 | news.google.comElixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board ... - GlobeNewswireNovember 18, 2022 | news.google.comGlobal Human Growth Hormones Deficiency (Ghd) Drug Market Upcoming Innovations, Companies, and Forec - PharmiWeb.comOctober 21, 2022 | news.google.comScrut Automation Hires Todd Dekkinga as Its Chief Information Security Officer - Press Trust of India - archive.ptinews.comOctober 12, 2022 | securitymagazine.comTodd Dekkinga named Chief Information Security Officer at Zluri - Security MagazineOctober 11, 2022 | prweb.comZluri Hires Todd Dekkinga as Chief Information Security Officer - PR WebOctober 11, 2022 | finance.yahoo.comZluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceOctober 9, 2022 | fiercebiotech.comPhase 3 flop puts Versartis on life support - FierceBiotechJuly 25, 2022 | thisisardee.ieHuman Growth Hormones Deficiency (GHD) Drugs Market Prospects & Upcoming s and Opportunities Analyzed for Coming Years – This Is Ardee - This Is ArdeeJune 29, 2022 | designerwomen.co.ukHuman Growth Hormones Deficiency (GHD) Drugs Market Revenue Growth, Key Players | Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc. – Designer Women - Designer WomenJune 15, 2022 | designerwomen.co.ukGlobal Human Growth Hormones Deficiency (Ghd) Drug Market 2022 Comprehensive Analysis, Business Growing Strategies, Industry Segmentation and Forecast 2028 – Designer Women - Designer WomenJune 13, 2022 | indiandefencenews.infoBlockchain Devices Market Size And Forecast to 2028 |Ledger SAS, HTC Corporation, General Bytes, Sikur, Pundi X Labs – Indian Defence News - Indian Defence NewsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsContext TherapeuticsNASDAQ:CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.LAVA TherapeuticsNASDAQ:LVTXLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Mainz BiomedNASDAQ:MYNZMainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.VersartisNASDAQ:VSARAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.